SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kosan BioSciences -- KOSN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (884)2/28/2008 11:41:30 PM
From: scaram(o)uche  Read Replies (1) of 933
 
>> at least that's the impression I have <<

So you go to the people who have the formulation advantage, and partner the package from a position of weakness?

No, there's no motilin agonist in the price. Nor should there be. Large markets. Somebody out there must have guidance re. royalty. Maybe 6%, sliding to 8%, wild-ass guess. Up front was 12.5m, or something of that magnitude. GSK has a motilin agonist in (?) phase I.

Does mlnm believe the "moderates velcade tox" bit?

Thanks for the comments re. i.p., gotta run.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News